TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35959845
Drug: SM DNA
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM DNA (530 mg day‐1)
Study: 35959845
Drug: SM DNA
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM DNA (530 mg day‐1) in males
Study: 35395776
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1 μg/kg and maintenance dose of 0.5 μg/kg/h)
Study: 32240562
Drug: Tag-7 gene-modified
Normalized name: Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tag-7 gene-modified tumor cells-based vaccine (GMV), injected subcutaneously every 3 weeks until progression or for 2 years.
Study: 32240562
Drug: Tag-7 gene-modified
Normalized name: Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tag-7 gene-modified tumor cells-based vaccine (GMV) in favorable prognosis (FP) group (MICA level ≤582 pg/mL, n = 15).
Study: 32240562
Drug: Tag-7 gene-modified
Normalized name: Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tag-7 gene-modified tumor cells-based vaccine (GMV).
Study: 36197845
Drug: Ad26.Filo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.Filo and MVA-BN-Filo vaccine regimens
Study: 34848351
Drug: Intrauterine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine administration of activated peripheral blood mononuclear cells (PBMC) at a dose of 1.106 cells on day 2 (D2) after stimulation with phytohemagglutinin (PHA) and human chorionic gonadotropin (hCG) for 48 hours.
Study: 32087143
Drug: 0.18 mg
Normalized name: naloxone 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 mg fluocinolone acetonide insert
Study: 34924394
Drug: Skin care
Normalized name: Skin Care
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin care plus makeup therapy (n = 18)
Study: 33944923
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives for statin therapy adherence
Study: 32449296
Drug: Oral capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsaicin
Study: 34270731
Drug: Opioids (use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (use of >40 morphine milligram equivalent before implantation)
Study: 35381867
Drug: Diuretics (DT)
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (DT)
Study: 32674237
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of red furu
Study: 32674237
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of tofu
Study: 32199021
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) only
Study: 34877731
Drug: Mean monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mean monthly reporting of ≥2 severe symptoms
Study: 34388396
Drug: Teclistamab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab (subcutaneous at 1500 μg/kg once per week after step-up doses of 60 μg/kg and 300 μg/kg)
Study: 34755760
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (50 mg/kg)
Study: 33373969
Drug: Doramectin 200
Normalized name: Doramectin
DrugBank: Doramectin (DB11400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doramectin 200 μg/kg live weight (LW)
Study: 33373969
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 1 mL/50 kg LW (Control)
Study: 33535224
Drug: Early insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insulin treatment in VLBW infants
Study: 32970162
Drug: Cystus® tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystus® tea mouthwash solution
Study: 32970162
Drug: Sage tea
Normalized name: Alberto VO5 Blackberry Sage Tea Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sage tea mouthwash solution
Study: 35457579
Drug: Yogurt group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt group (YGT-G) consuming a yogurt drink (9.3 g protein, 39 g CHO, 192 kcal) after IWT
Study: 35775194
Drug: MPS1 Inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPS1 Inhibitor (BAY 1217389) in combination with Paclitaxel
Study: 32476258
Drug: COVID-19 treatment
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 treatment modalities in SOT patients
Study: 32757504
Drug: Individually uptitrated,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually uptitrated, high-dose baclofen (30-300 mg/d)
Study: 39292112
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy (MT)
Study: 33019775
Drug: SPOTONE ML
Normalized name: Apoptone
DrugBank: Apoptone (DB06307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPOTONE ML predictor
Study: 32004317
Drug: Clinical decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical decision rule (Feverkidstool) guiding antibiotic prescription.
Study: 35367170
Drug: Only Dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only Dual Antiplatelet Therapy (DAPT)
Study: 35367170
Drug: Low-dose rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rivaroxaban (2.5 mg twice daily for 30 days) + DAPT
Study: 35031521
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care plus a twice‐daily application‐based mindful meditation program
Study: 35028170
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal cream
Study: 32532326
Drug: Extended doxycycline
Normalized name: doxycycline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended doxycycline treatment (100 mg twice daily for 1 week before and after oocyte retrieval)
Study: 33834625
Drug: Pre‐workout supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐workout supplements
Study: 35138529
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/day
Study: 35608694
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with 450-nm blue LED and curcumin photosensitizer
Study: 35608694
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) with low-level laser therapy
Study: 35833528
Drug: Conventional Non-Surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Non-Surgical Therapy (CNST)
Study: 33272623
Drug: 6 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 μg/d of follitropin delta
Study: 33272623
Drug: 9 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 μg/d of follitropin delta
Study: 34330170
Drug: suvorexant 20
Normalized name: suvorexant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvorexant 20 mg
Study: 34622762
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg or 300 mg every four weeks
Study: 36458325
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg and colloidal bismuth 200 mg each given twice a day for 10 days (V10)
Study: 36458325
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg daily (V10)
Study: 36458325
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg daily (V14)
Study: 32960847
Drug: PD-1 inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab)
Study: 33378989
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of favipiravir and tocilizumab
Study: 34301226
Drug: LEAP (CompuLsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEAP (CompuLsive Exercise Activity TheraPy)
Study: 32692000
Drug: COVID-19 treatment
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 treatment in emergency departments
Study: 33023276
Drug: Nuun electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuun electrolyte tablets (double dose)
Study: 39593191
Drug: Tamoxifen 1
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 1 mg
Study: 39593191
Drug: Tamoxifen 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 2.5 mg
Study: 39593191
Drug: Tamoxifen 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 5 mg
Study: 39593191
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg
Study: 34221078
Drug: Backward Walking
Normalized name: Backaid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Backward Walking (BW) combined with conventional treatments
Study: 34221078
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments alone (Control Group)
Study: 32505495
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or comparator medication
Study: 33631065
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg per kilogram of body weight)
Study: 33631065
Drug: Sarilumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab (400 mg)
Study: 32596348
Drug: Caffeine mouth
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine mouth rinse (300 mg of caffeine in 25 mL of water)
Study: 32596348
Drug: Placebo (microcrystalline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (microcrystalline cellulose in 25 mL of water)
Study: 34226233
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (cMDA) for soil-transmitted helminths, costing averaged US$1.14 per person per round in the first year of the trial, net of drugs.
Study: 35417763
Drug: Moderate hypofractionation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypofractionation (MHF) - 70 Gy in 28 daily fractions
Study: 33554587
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 supplementation
Study: 33554587
Drug: Medium-dose vitamin
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose vitamin D3 supplementation
Study: 33554587
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D3 supplementation
Study: 34376277
Drug: Mild anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild anemia group (Hb 10≤ Hb <13 g/dl for men and 10≤ Hb <12 g/dl for women)
Study: 34376277
Drug: Non-anemia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anemia group (Hb ≥13 g/dl for men and Hb ≥12 g/dl for women)
Study: 35513779
Drug: Progesterone therapy
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone therapy
Study: 36189549
Drug: 0.2% Glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Glyceryl Trinitrate (GTN) ointment
Study: 34157116
Drug: DHEAS (measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEAS (measured in μmol/L)
Study: 33980157
Drug: Polypharmacy (use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (use of five or more medications)
Study: 32327254
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose treatment
Study: 35463130
Drug: nVNS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nVNS therapy plus standard of care (SoC)
Study: 35120656
Drug: Standard-of-care strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care strategy with ustekinumab (6 mg/kg IV at baseline, 90 mg SC at week 8, and potential escalation per European labelling)
Study: 32669099
Drug: TXA 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 1.5 g administered 30 min before the operation
Study: 36414207
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health intervention (DHI) including digital monitoring of sleep, meals, and physical activity plus weekly motivational health coaching
Study: 36414207
Drug: Enhanced usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced usual care (EUC) consisting of weekly telephone calls and similar assessment schedules
Study: 32635494
Drug: Oceanix (OCX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oceanix (OCX) 25 mg for 14 days
Study: 32635494
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + OCX 2 (5.1 mg/day)
Study: 32635494
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + OCX 1 (2.55 mg/day)
Study: 33848758
Drug: Combination NRT
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination NRT
Study: 35724670
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg plus FDCSL (400/90 mg)
Study: 35724670
Drug: FDCSL (400/90
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDCSL (400/90 mg) alone
Study: 32810088
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (30 units in 1000ml normal saline at 15 units/hour during surgery)
Study: 33959169
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 U weekly for 6 weeks followed by 1000 U daily for deficiency; 1000 U daily for insufficiency)
Study: 34128999
Drug: Eptinezumab, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptinezumab, 100 mg
Study: 33030563
Drug: MK-7 (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 (375 μg daily)
Study: 35761355
Drug: Cervical Collar
Normalized name: Cervical Collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical Collar (CC)
Study: 34839318
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 mg/kg administered after rocuronium infusion)
Study: 33493368
Drug: SYN023 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN023 (0.3 mg/kg, 1.0 mg/kg, 2.0 mg/kg) via intramuscular injection
Study: 33493368
Drug: SYN023 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN023 (0.3 mg/kg) via subcutaneous injection
Study: 33493368
Drug: SYN023 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN023 (0.3 mg/kg) via intramuscular or subcutaneous injection
Study: 33493368
Drug: SYN023 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN023 (higher doses)
Study: 32052341
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with chemotherapy
Study: 35956389
Drug: Chitosan-derived glucosamine
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan-derived glucosamine (1500 mg glucosamine sulfate 2KCl)
Study: 35956389
Drug: Biofermentation-derived glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofermentation-derived glucosamine (1500 mg glucosamine sulfate 2KCl)
Study: 32569678
Drug: 94 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 94 µg/day TMG
Study: 32569678
Drug: 147 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 147 µg/day TMG
Study: 32569678
Drug: 184 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 184 µg/day TMG
Study: 33819140
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin started 12 hours postoperatively at 10 UI/kg per hour
Study: 33819140
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin treatment
Study: 32498426
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (AA mixture engineered to prolong AA absorption with Physiomimic TechnologyTM)
Study: 35470085
Drug: Half-dose photodynamic
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose photodynamic therapy (PDT) for 12 weeks
Study: 32246432
Drug: Caregiver FACT-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver FACT-G
Study: 32006516
Drug: MMR+V (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR+V (combined measles-mumps-rubella-varicella vaccine)
Study: 96312189
Drug: Buprenorphine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (6 mg i.m.)
Study: 96312189
Drug: Morphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (30 mg i.m.)
Study: 96312189
Drug: Naloxone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.3 mg)
Study: 35475793
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment for 3 consecutive weeks based on routine conventional treatment
Study: 35475793
Drug: Routine conventional
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine conventional treatment alone
Study: 32864685
Drug: MTX (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (20 mg/week)
Study: 34579020
Drug: CARET +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARET + broccoli supplement (TS)
Study: 34579020
Drug: control +
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control + broccoli supplement (S)
Study: 32243385
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of granisetron (control)
Study: 35226724
Drug: Automated boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated boluses (ropivacaine 0.2% as 8 ml every 2 h, initiated 5 h after discharge)
Study: 35226724
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (ropivacaine 0.2% as 6 ml/h, initiated before discharge)
Study: 34246358
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (3 µg inactivated SARS-CoV-2 virion) administered intramuscularly on days 0 and 14
Study: 36056778
Drug: Ruxolitinib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (25 mg orally twice daily in continuous 28-day cycles)
Study: 33105861
Drug: Kudzu flower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kudzu flower and mandarin peel extract (KM) 1150 mg/day
Study: 35368058
Drug: Alirocumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (150 mg biweekly for 52 weeks)
Study: 32434975
Drug: Controlled-release drugs
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release drugs - chlorhexidine gel
Study: 34918443
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg.kg-1)
Study: 34918443
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg.kg-1)
Study: 35789991
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (60,000 international units monthly for 5 years)
Study: 35789991
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (60,000 international units monthly for 5 years) in adults aged ≥70 years
Study: 33372392
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 1000 IU and Calcium 1000 mg daily for 6 weeks (Group A)
Study: 33372392
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 250 IU and Calcium 500 mg daily for 6 weeks (Group B)
Study: 32525863
Drug: Routine enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine enteral nutrition (1kcal/mL)
Study: 32501612
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for type 2 diabetes (specific treatments not detailed)
Study: 34231281
Drug: gel vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel vehicle
Study: 33856355
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy
Study: 36795388
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (control)
Study: 32763021
Drug: Ketamine (0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.44 mg/kg intravenous dose)
Study: 34717750
Drug: Video Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video Intervention Therapy (VIT)
Study: 34161146
Drug: Flaxseed (40-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (40-g packets daily before and during radiotherapy)
Study: 36104059
Drug: ESPB (Erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPB (Erector Spinae Plane Block) with 20 mL of 0.25% bupivacaine